Streetbeat News

Revenues

VSTS

Analyst ratings for Vestis (NYSE:VSTS) have varied over the past three months, with recent updates showing a shift towards a more bearish outlook. The average 12-month price target has increased to $21.00 from $17.00, indicating a positive sentiment shift. Vestis, a provider of uniform rentals and workplace supplies, has shown a revenue growth of 2.46% but struggles with profitability and debt management. The company's market capitalization is below the industry average, suggesting it is smaller compared to peers.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

PRVA

Privia Health Gr (NASDAQ:PRVA) has been evaluated by 4 analysts over the last three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $25.25, a decrease from the previous $28.33. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Privia Health Gr, a technology-driven physician-enablement company, shows strong net margin and ROE but lags in revenue growth and ROA compared to industry peers. Its market capitalization and debt management indicate a smaller scale and conservative financial approach.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

GPOR

Gulfport Energy (NYSE:GPOR) has received mixed analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target for GPOR has been raised to $154.6, indicating a slight increase from the previous target. Financial analysis reveals challenges in revenue growth and market capitalization but highlights strong profitability metrics such as net margin, ROE, and ROA. GPOR's debt management is also noted positively.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

EDIT

Editas Medicine (NASDAQ:EDIT) has seen a positive shift in analyst ratings over the last three months, with an average 12-month price target now at $14.00, up 27.27% from $11.00. Analysts from Citigroup, Barclays, JP Morgan, and Truist Securities have all raised their price targets, reflecting optimism about the company's future performance. Editas Medicine, a genome editing company, has shown remarkable financial health with a revenue growth rate of 12604.76% as of September 30, 2023, and strong market capitalization, net margin, ROE, and ROA figures.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

RLJ

RLJ Lodging (NYSE:RLJ) has been analyzed by 5 analysts, showing a mix of bullish to indifferent sentiments. Recent ratings reveal an average 12-month price target of $14.1, marking a 10.59% increase from the previous target. Analysts from Oppenheimer, Wolfe Research, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, reflecting optimism. Despite this, RLJ faces revenue challenges, with a -4.4% growth over 3 months, and struggles in profitability and asset utilization, indicated by low net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

BCO

SAEF

Brink's Company (NYSE:BCO) reported Q4 fiscal 2023 earnings with a 5% year-on-year sales growth to $1.246 billion, slightly missing analyst estimates. Adjusted EPS of $2.76 exceeded expectations. Revenue varied across regions, with North America seeing a decrease, while Latin America and Europe experienced growth. Adjusted operating profit and EBITDA saw year-on-year increases. The company has set optimistic targets for FY24, expecting mid-single digit revenue growth and adjusted EPS of $7.30 - $8.00. The Schwab Ariel ESG ETF (NYSE:SAEF), with 3% exposure to Brink's, gained about 5% last month. BCO shares were up 2.5% following the announcement.

Portfolio Pulse from Anusuya Lahiri

February 29, 2024 | 4:56 pm

OPRA

Opera Limited (NASDAQ:OPRA) reported a 17% year-on-year increase in Q4 fiscal 2023 revenue to $113.00 million, surpassing the consensus of $112.2 million. EPS per ADS was $1.38, beating the consensus of $0.23, leading to a stock price gain. Monthly active users reached 313 million, with the Opera GX browser user base at 27.8 million, up 7% Q/Q. Search revenue grew by 15% Y/Y to $44.7 million, and advertising revenue increased by 20% Y/Y to $67.8 million. Operating expenses rose by 10% Y/Y, but the adjusted EBITDA margin improved by 90 bps to 24.6%. Opera held $93.9 million in cash and equivalents and generated $25.3 million in operating cash flow. The company expects fiscal 2024 revenue of $450 million to $465 million. OPRA shares were up 2.04% at $11.86.

Portfolio Pulse from Anusuya Lahiri

February 29, 2024 | 4:43 pm

PZZA

Papa John's International, Inc. (NASDAQ:PZZA) shares rose after reporting Q4 adjusted earnings per share of 91 cents, surpassing expectations of 72 cents. However, net sales of $571.32 million fell short of the $577.86 million forecast. Revenues increased by 9% year over year, with North America sales up 2% and International sales down 6%. The company saw 89 net unit openings and reported a 17.5% increase in operating income to $42.6 million. Global system-wide restaurant sales grew by 11% to $1.34 billion, excluding foreign currency impacts. PZZA shares increased by 6.74% to $74.88.

Portfolio Pulse from Nabaparna Bhattacharya

February 29, 2024 | 4:27 pm

EQNR

Equinor (EQNR) has been awarded an offtake contract for its Empire Wind 1 project in New York's fourth offshore wind solicitation round. This marks a significant step forward for Equinor's expansion in renewable energy within the U.S. market.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 4:25 pm

SPY

Fed's Goolsbee indicates that the impact of supply shocks on inflation is delayed, suggesting that the benefits to disinflation from improvements in the supply chain are yet to be realized.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 4:23 pm